4 Results for "

antigen presentation studies

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "antigen presentation studies" in MCE Product Catalog:

Cat. No.: HY-NP141
Synonyms: 4-Hydroxy-3-nitrophenylacetyl-bovine serum albumin
NP-BSA (4-Hydroxy-3-nitrophenylacetyl-bovine serum albumin) is an antigen-adjuvant conjugate of 4-Hydroxy-3-nitrophenylacetyl (NP) conjugated to bovine serum albumin (BSA), which is an immune complex. NP-BSA is taken up, processed, and presented by antigen-presenting cells to stimulate T-cell proliferation and the production of antigen-specific antibodies. NP-BSA can be used in the research of immunological vaccines .
loading...
    loading...
Cat. No.: HY-176755
CAS No.: 943316-60-7
Research Areas:  

Inflammation/Immunology

CCL-34 is a Toll-like receptor 4 (TLR4) activator. CCL-34 significantly induced dendritic cell (DC) CD83 expression and IL-12p70 production in a dose-dependent manner, thereby inducing DC maturation. CCL-34 enhanced the allostimulatory activity of DC on naive CD4+CD45+RA+ T cell proliferation and IFN-γ secretion. CCL-34 further induced antigen presentation ability in mice inoculated with doxorubicin-treated colorectal cancer cells. CCL-34 can be used in studies of immune stimulation.
loading...
    loading...
Cat. No.: HY-P5488
CAS No.: 329696-53-9
Target:  

Peptides

Research Areas:  

Others

BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)
loading...
    loading...
Cat. No.: HY-P990716
CAS No.: 2648346-74-9
Synonyms: AZD7789

Target:  

PD-1/PD-L1 Tim3

Research Areas:  

Inflammation/Immunology

Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .
loading...
    loading...